Latest Earnings Results: Q2 '26
Estimated EPS
$0.03
Reported EPS
-$0.23
Surprise
-962.49%
Estimated Rev
$46.12M
Reported Rev
$44.2M
Surprise
-4.17%
• Reported GAAP EPS of -$0.23 down -330.00% YoY • Reported revenue of $44.23M down -9.48% YoY • Biote Corp. expects revenue to be above $175 million and Adjusted EBITDA to be above $25 million for the full-year 2026, with dietary supplements revenue growing at a mid-single-digit rate.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.00 | -- | -- | N/A |
Q2 '26 | $0.03 | -$0.23 | -962.49% | MISSED |
Q1 '26 | $0.05 | $0.06 | 26.32% | BEAT |
Q4 '25 | $0.04 | $0.06 | 50.00% | BEAT |
Q3 '25 | $0.08 | $0.22 | 183.87% | BEAT |